retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% A Study of Retatrutide (LY3437943)

Prioritize protein at every meal This is the single most impactful dietary change

With that caveat, here is what the published Phase 3 data say at peak dose, in adults with obesity and without diabetes: The roughly 6-percentage-point gap between retatrutide and tirzepatide at peak dose, sustained across more than 2,000 participants, is the data point payers and prescribers will spend the next year arguing about

Weight loss visible and steady

Your gut isnt just about digestionits the foundation of your overall health.

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Patel D., Smith A

Times have changed a bit and newer and larger studies have been done since that time